Trials / Completed
CompletedNCT00910351
Cipro Inhaler for Cystic Fibrosis Children Ages 6-12
A Study to Evaluate the Safety and Pharmacokinetics of Ciprofloxacin in Adults and Children Aged 6 - 12 Years With Cystic Fibrosis Following Inhalation of Ciprofloxacin Dry Powder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
Ciprofloxacin PulmoSphere Inhalation Powder appears to be an effective and adequate antibiotic treatment for cystic fibrosis patients with P. aeruginosa colonisation. This planned study is the first study on the use of this new Ciprofloxacin PulmoSphere Inhalation Powder in the pediatric population of 6 to 12 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciprofloxacin (Cipro, BAYQ3939) | 25 mg inhaled Ciprofloxacin |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2009-05-29
- Last updated
- 2013-11-21
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00910351. Inclusion in this directory is not an endorsement.